Posted On: 20 Jun 2025
Botanix Pharmaceuticals has been featured in Dr Boreham’s Crucible, a column focusing on the Australian biotechnology and healthcare sectors. The interview with CEO, Dr Howie McKibbon includes in-depth look at Botanix and its fulfilment platform, commercialization strategies, company history, and an update on the launch of Sofdra™ (sofpironium) gel, 12.45% in the US.